Amundi
ABCL icon

Amundi’s AbCellera Biologics ABCL Stock Holding History

Amundi’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-26,567
Closed -$113K – 1999
2023
Q3 		$113K Hold
26,567
– – ﹤0.01% 1731
2023
Q2 		$175K Hold
26,567
– – ﹤0.01% 1637
2023
Q1 		$190K Buy
26,567
+9,790
+58% +$88.9K ﹤0.01% 1583
2022
Q4 		$161K Sell
16,777
-7,100
-30% -$82K ﹤0.01% 1543
2022
Q3 		$268K Hold
23,877
– – ﹤0.01% 1421
2022
Q2 		$265K Buy
+23,877
New +$202K ﹤0.01% 1334

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Amundi's ABCL Position: Q4 2023 in Review

Amundi sold out of AbCellera Biologics (ABCL) in Q4 2023, closing a stake of 26,567 shares — an estimated $113K sold.

Amundi first reported a position in ABCL in Q2 2022 and held it in 6 quarters. The position peaked at $268K in Q3 2022. 142 funds tracked by Wall St. Rank hold ABCL as of Q4 2023.

  • Amundi reported no remaining AbCellera Biologics position as of Q4 2023 after selling out during the quarter.
  • Amundi sold 26,567 AbCellera Biologics shares in Q4 2023, an estimated $113K.
  • Amundi first reported a position in AbCellera Biologics in Q2 2022 and held it in 6 quarters.
  • Amundi's AbCellera Biologics position peaked at $268K in Q3 2022.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2023.

Based on Amundi's 13F filing for Q4 2023, filed 14 Feb 2024.